在本文中,与一般分子式将[RuCl了一系列新的钌(II)络合物2(芳烃)(NHC)],(芳烃= η 6 - p -cymene,NHC = Ñ -杂环卡宾)从合成原位制备通过过渡金属化法制备银(I)-NHC。这些配合物已通过分析和光谱方法进行了全面表征。钌(II)配合物被测试为在外部酸性添加剂存在下通过氢转移将N-甲基哌啶与各种醛选择性进行β-C(sp 3)-H官能化的有前途的催化剂。这些环保的交叉脱氢偶联剂可以生产C(3)-烷基化的N-不带烯胺的-甲基哌啶衍生物,仅二氧化碳和水为良性副产物。
[EN] AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS<br/>[FR] AMINOPYRROLOTRIAZINES EN TANT QU'INHIBITEURS DE KINASE
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2019147782A1
公开(公告)日:2019-08-01
The disclosure relates to compounds of formula I which are useful as kinase modulators including RIPK1 modulation. The disclosure also provides methods of making and using the compounds for example in treatments related to necrosis or inflammation as well as other indications.
NITROGEN-CONTAINING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF ATRIAL FIBRILLATION
申请人:Oshima Kunio
公开号:US20120225866A1
公开(公告)日:2012-09-06
The present invention provides a novel diazepine compound that blocks the I
Kur
current or the Kv1.5 channel potently and more selectively than other K
+
channels. The present invention relates to a diazepine compound represented by General Formula (1)
or a salt thereof,
wherein R
1
, R
2
, R
3
, and R
4
are each independently hydrogen, lower alkyl, cyclo lower alkyl or lower alkoxy lower alkyl;
R
2
and R
3
may be linked to form lower alkylene;
A
1
is lower alkylene optionally substituted with one or more substituents selected from the group consisting of hydroxyl and oxo;
Y
1
and Y
2
are each independently —N═ or —CH═;
and
R
5
is group represented by
wherein R
6
and R
7
are each independently hydrogen or organic group;
R
6
and R
7
may be linked to form a ring together with the neighboring group —X
A
—N—X
B
—;
X
A
and X
B
are each independently a bond, lower alkylene, etc.
Compounds having formula (I) (IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein: (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX).